{"id":6999,"date":"2014-10-21T22:00:00","date_gmt":"2014-10-21T22:00:00","guid":{"rendered":"https:\/\/www.nicox.com\/approbation-de-lacquisition-daciex-therapeutics-inc-par-les-actionnaires-de-nicox\/"},"modified":"2014-10-21T22:00:00","modified_gmt":"2014-10-21T22:00:00","slug":"approbation-de-lacquisition-daciex-therapeutics-inc-par-les-actionnaires-de-nicox","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/approbation-de-lacquisition-daciex-therapeutics-inc-par-les-actionnaires-de-nicox\/","title":{"rendered":"Approbation de l\u2019acquisition d\u2019Aciex Therapeutics, Inc. par les actionnaires de Nicox"},"content":{"rendered":"<div>\n Sophia Antipolis, France.<\/div>\n<div>\n &nbsp;<\/div>\n<div>\n <strong>Nicox S.A. <\/strong>(NYSE Euronext Paris : COX), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que ses actionnaires ont vot\u00e9 en faveur de l\u2019acquisition d\u2019Aciex Therapeutics, Inc., une soci\u00e9t\u00e9 pharmaceutique am\u00e9ricaine de d\u00e9veloppement en ophtalmologie, \u00e0 capitaux priv\u00e9s, dans le cadre de l\u2019Assembl\u00e9e G\u00e9n\u00e9rale tenue ce jour, le 22 octobre 2014, avec plus de 97% de votes positifs. La r\u00e9alisation d\u00e9finitive de l\u2019op\u00e9ration est pr\u00e9vue dans les prochains jours apr\u00e8s r\u00e9alisation de certaines conditions et formalit\u00e9s juridiques. Toutes les autres r\u00e9solutions soumises \u00e0 l\u2019Assembl\u00e9e G\u00e9n\u00e9rale ont \u00e9galement \u00e9t\u00e9 approuv\u00e9es.<\/div>\n<div>\n &nbsp;<\/div>\n<div>\n L\u2019acquisition d\u2019Aciex constitue une \u00e9tape majeure dans la strat\u00e9gie de Nicox visant \u00e0 cr\u00e9er une soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie et permettra d\u2019\u00e9largir et de renforcer de fa\u00e7on significative le portefeuille th\u00e9rapeutique de Nicox. Le portefeuille de m\u00e9dicaments en d\u00e9veloppement d\u2019Aciex inclut :<\/div>\n<div>\n &nbsp;<\/div>\n<div>\n \u2022&nbsp;<span class=\"Apple-tab-span\" span=\"\">l\u2019AC-170 pour la conjonctivite allergique, pour lequel deux essais cliniques de phase 3 ont \u00e9t\u00e9 compl\u00e9t\u00e9s et pour lequel Nicox pr\u00e9voit de demander une r\u00e9union de pr\u00e9-NDA d\u2019ici la fin du premier trimestre 2015, avant la soumission d\u2019un dossier de demande d\u2019autorisation de mise sur le march\u00e9 aux Etats-Unis <em>(New Drug Application, NDA)<\/em> ;&nbsp;<\/span><\/div>\n<div>\n &nbsp;<\/div>\n<div>\n \u2022&nbsp;<span class=\"Apple-tab-span\" span=\"\">l\u2019AC-155 pour l&rsquo;inflammation et la douleur oculaires postop\u00e9ratoires, pour lequel des \u00e9tudes de phase 2 devraient \u00eatre initi\u00e9es en 2015, sous r\u00e9serve d\u2019accord de la FDA.&nbsp;<\/span><\/div>\n<div>\n &nbsp;<\/div>\n<div>\n A la r\u00e9alisation d\u00e9finitive de l\u2019op\u00e9ration, Nicox \u00e9mettra 20 627 024 actions Nicox nouvelles en \u00e9change de 100% des actions Aciex. L\u2019op\u00e9ration inclut \u00e9galement un compl\u00e9ment de r\u00e9mun\u00e9ration d&rsquo;apport pour une valeur suppl\u00e9mentaire pouvant atteindre un maximum de $55 millions, sous forme de bons d&rsquo;attribution d&rsquo;actions Nicox dont l&rsquo;exercice serait conditionn\u00e9 \u00e0 l&rsquo;obtention, dans un d\u00e9lai pr\u00e9d\u00e9fini, d&rsquo;approbations r\u00e9glementaires par la <em>Food and Drug Administration <\/em>(FDA) am\u00e9ricaine pour le produit AC-170 et deux produits suppl\u00e9mentaires non divulgu\u00e9s.<\/div>\n<div>\n &nbsp;<\/div>\n<div>\n Les actionnaires ont \u00e9galement approuv\u00e9 la nomination au Conseil d\u2019administration de Les Kaplan, Directeur G\u00e9n\u00e9ral d&rsquo;<em>Aciex Therapeutics, Inc.<\/em> et ancien Vice-pr\u00e9sident ex\u00e9cutif et Pr\u00e9sident de la Recherche et D\u00e9veloppement d&rsquo;Allergan, Inc.&nbsp;<\/div>\n<div>\n &nbsp;<\/div>\n<div>\n Pour plus d\u2019informations, veuillez consulter le&nbsp;<a class=\"nx-file\" href=\"https:\/\/www.nicox.com\/assets\/files\/pr2014070200fr3.pdf\">communiqu\u00e9 de presse Nicox du 2 juillet 2014<\/a>&nbsp;et le \u00ab<a class=\"nx-file\" href=\"\">Document E<\/a>&nbsp;\u00bb enregistr\u00e9 aupr\u00e8s de l\u2019AMF le 30 septembre 2014 sous le num\u00e9ro E.14-060&nbsp;(disponible sur le site Internet de Nicox <a href=\"https:\/\/www.nicox.com\">www.nicox.com<\/a>, rubrique Espace Investisseurs \/ Assembl\u00e9es G\u00e9n\u00e9rales).<\/div>\n<div>\n &nbsp;<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sophia Antipolis, France. &nbsp; Nicox S.A. (NYSE Euronext Paris : COX), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que ses actionnaires ont vot\u00e9 en faveur de l\u2019acquisition d\u2019Aciex Therapeutics, Inc., une soci\u00e9t\u00e9 pharmaceutique am\u00e9ricaine de d\u00e9veloppement en ophtalmologie, \u00e0 capitaux priv\u00e9s, dans le cadre de l\u2019Assembl\u00e9e G\u00e9n\u00e9rale tenue ce jour, le 22 octobre 2014, avec [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[32,16],"tags":[],"class_list":["post-6999","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-media"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Approbation de l\u2019acquisition d\u2019Aciex Therapeutics, Inc. par les actionnaires de Nicox - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/approbation-de-lacquisition-daciex-therapeutics-inc-par-les-actionnaires-de-nicox\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Approbation de l\u2019acquisition d\u2019Aciex Therapeutics, Inc. par les actionnaires de Nicox - Nicox\" \/>\n<meta property=\"og:description\" content=\"Sophia Antipolis, France. &nbsp; Nicox S.A. (NYSE Euronext Paris : COX), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que ses actionnaires ont vot\u00e9 en faveur de l\u2019acquisition d\u2019Aciex Therapeutics, Inc., une soci\u00e9t\u00e9 pharmaceutique am\u00e9ricaine de d\u00e9veloppement en ophtalmologie, \u00e0 capitaux priv\u00e9s, dans le cadre de l\u2019Assembl\u00e9e G\u00e9n\u00e9rale tenue ce jour, le 22 octobre 2014, avec [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/approbation-de-lacquisition-daciex-therapeutics-inc-par-les-actionnaires-de-nicox\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"2014-10-21T22:00:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/approbation-de-lacquisition-daciex-therapeutics-inc-par-les-actionnaires-de-nicox\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/approbation-de-lacquisition-daciex-therapeutics-inc-par-les-actionnaires-de-nicox\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Approbation de l\u2019acquisition d\u2019Aciex Therapeutics, Inc. par les actionnaires de Nicox\",\"datePublished\":\"2014-10-21T22:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/approbation-de-lacquisition-daciex-therapeutics-inc-par-les-actionnaires-de-nicox\\\/\"},\"wordCount\":471,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\",\"Actualit\u00e9s et M\u00e9dia\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/approbation-de-lacquisition-daciex-therapeutics-inc-par-les-actionnaires-de-nicox\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/approbation-de-lacquisition-daciex-therapeutics-inc-par-les-actionnaires-de-nicox\\\/\",\"name\":\"Approbation de l\u2019acquisition d\u2019Aciex Therapeutics, Inc. par les actionnaires de Nicox - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"2014-10-21T22:00:00+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/approbation-de-lacquisition-daciex-therapeutics-inc-par-les-actionnaires-de-nicox\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Approbation de l\u2019acquisition d\u2019Aciex Therapeutics, Inc. par les actionnaires de Nicox - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/approbation-de-lacquisition-daciex-therapeutics-inc-par-les-actionnaires-de-nicox\/","og_locale":"fr_FR","og_type":"article","og_title":"Approbation de l\u2019acquisition d\u2019Aciex Therapeutics, Inc. par les actionnaires de Nicox - Nicox","og_description":"Sophia Antipolis, France. &nbsp; Nicox S.A. (NYSE Euronext Paris : COX), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que ses actionnaires ont vot\u00e9 en faveur de l\u2019acquisition d\u2019Aciex Therapeutics, Inc., une soci\u00e9t\u00e9 pharmaceutique am\u00e9ricaine de d\u00e9veloppement en ophtalmologie, \u00e0 capitaux priv\u00e9s, dans le cadre de l\u2019Assembl\u00e9e G\u00e9n\u00e9rale tenue ce jour, le 22 octobre 2014, avec [&hellip;]","og_url":"https:\/\/www.nicox.com\/fr\/approbation-de-lacquisition-daciex-therapeutics-inc-par-les-actionnaires-de-nicox\/","og_site_name":"Nicox","article_published_time":"2014-10-21T22:00:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/approbation-de-lacquisition-daciex-therapeutics-inc-par-les-actionnaires-de-nicox\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/approbation-de-lacquisition-daciex-therapeutics-inc-par-les-actionnaires-de-nicox\/"},"author":{"name":"","@id":""},"headline":"Approbation de l\u2019acquisition d\u2019Aciex Therapeutics, Inc. par les actionnaires de Nicox","datePublished":"2014-10-21T22:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/approbation-de-lacquisition-daciex-therapeutics-inc-par-les-actionnaires-de-nicox\/"},"wordCount":471,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s","Actualit\u00e9s et M\u00e9dia"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/approbation-de-lacquisition-daciex-therapeutics-inc-par-les-actionnaires-de-nicox\/","url":"https:\/\/www.nicox.com\/fr\/approbation-de-lacquisition-daciex-therapeutics-inc-par-les-actionnaires-de-nicox\/","name":"Approbation de l\u2019acquisition d\u2019Aciex Therapeutics, Inc. par les actionnaires de Nicox - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"2014-10-21T22:00:00+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/approbation-de-lacquisition-daciex-therapeutics-inc-par-les-actionnaires-de-nicox\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/6999","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=6999"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/6999\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=6999"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=6999"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=6999"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}